Ze’ev Weinfeld

Ze’ev Weinfeld

With three decades in leadership roles in the life sciences industry and in technology development and commercialization, Ze’ev most recently was the CEO of MEDX Xelerator prior to which he founded and managed miCure Therapeutics. Earlier, he negotiated and executed multi-million dollar commercialization agreements for a wide range of hi-tech and life sciences inventions as CEO of Ramot, Tel Aviv University’s technology transfer company. Prior to his appointment as CEO, he served as Ramot’s EVP, Business Development and VP, Intellectual Property and Business Development, directing multiple aspects of new technology assessment and strategic planning. Previously, Ze’ev was with Biosense Webster, a Johnson & Johnson company, where he was Director of Image Guided Surgery and Intellectual Property and a member of the management team in Israel. Ze’ev began his career at Elscint Ltd.’s Nuclear Medicine Division (now part of GE). His positions in the R&D and Marketing Departments involved leading all activities from design concept through R&D, regulatory approval and marketing of medical device products.

Ze’ev holds a PhD in Physics from Tel Aviv University.